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Objective: To test the ability of both zinc oxide nanoparticles (ZnONPs) and silver
nanoparticles (SNPs) to ameliorate the oxidative stress resulted from diabetes in diabetic
rats.
Methods: Fifty male albino rats were used; ten of them were served as control group and
forty, as the experiment group, were injected with streptozotocin at the single intraperi-
toneal dose of 100 mg/kg. Then, the experiment group was subdivided into, diabetic,
diabetic + ZnONPs, diabetic + SNPs and diabetic + insulin groups. The activities and
mRNA expression levels of superoxide dismutase, catalase, glutathione peroxidase and
glutathione reductase were determined in brain tissues. Malondialdehyde, total antioxi-
dant capacity, zinc and silver concentrations were estimated in the brain tissues of all rats.
Results: A signiﬁcant increase in the activities and mRNA expression levels of super-
oxide dismutase, catalase, glutathione peroxidase and glutathione reductase was shown.
Malondialdehyde levels were signiﬁcantly decreased while there was a signiﬁcant in-
crease in the zinc, silver concentrations and total antioxidant capacity in brain of ZnONPs
and SNPs treated rats, compared with diabetic or diabetic + insulin group and their
control group.
Conclusions: ZnONPs and SNPs can be used to ameliorate the oxidative stress in brain
resulted from diabetes mellitus.1. Introduction
Diabetes mellitus is referring to a group of metabolic im-
pairments characterized by highly raised blood glucose levels
[1]. The most consequence of diabetes mellitus is the generation
of reactive oxygen species (ROS) [2]. The ROS can induce b-cell
failure and develop insulin resistance [3]. Diabetes mellitus can
directly affect brain cells, through the generation of an
oxidative stress leading to apoptosis [4]. The key mechanism is
illustrated as an increase in glucose metabolism due to
hyperglycemia that promotes mitochondrial respiration,
resulting in release of superoxide and other reactive oxygen or
nitrogen species into the cytoplasm [5]. Zinc has been reported
to play a direct role in glucose homeostasis by enhancinghepatic glycogenesis through its actions on the insulin
signaling pathway and thus improves glucose utilization [6],
inhibits intestinal glucose absorption [7], and increases glucose
uptake in skeletal muscle and adipose tissue [6]. Moreover,
zinc is reported to inhibit glucagon secretion [8], thus reducing
gluconeogenesis and glycogenolysis, and it also enhances the
structural integrity of insulin [9]. Decreased zinc in the
pancreas may reduce the ability of the islet b-cells to
synthesize and lead insulin into blood [10]. Furthermore,
knowing zinc's antioxidant role, reduced zinc may exacerbate
the oxidative stress-mediated complications of diabetes. The
pivotal role of zinc in diabetes mellitus was discovered by
supplementation studies in diabetic rats [11]. In recent years,
there is a great development of nanotechnology in the ﬁeld of
science and technology; and metallic nanoparticles, like gold,
silver nanoparticles (SNPs), zinc oxide nanoparticles
(ZnONPs) and metal oxide nanoparticles, have shown great
challenges in the ﬁeld of medicine [12]. In a previous study,
we proved the antidiabetic effect of ZnONPs and SNPs as a
novel agent to control diabetes mellitus in rats [13]. The aim ofan open access article under the CC BY-NC-ND
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the oxidative stress induced by diabetes mellitus in brain tissues
of diabetic rats.
2. Materials and methods
2.1. Animals
Fifty male albino rats weighed (120 ± 20) g at the beginning
of the experiment. All the rats were ﬁrst grouped into two
groups: (1) control group (n = 10) without any treatments; (2)
experiment group, including the remaining forty animals, which
were induced to be diabetic through intraperitoneal injection of
single dose (100 mg/kg) of streptozotocin (Sigma–Aldrich,
Catalog No. S0130 SIGMA, Seelze, Germany). Then, the
experiment group was further divided into four groups: (1)
diabetic group (n = 10), which served as a positive control with
no treatment; (2) diabetic + ZnONPs group (n = 10), which was
administered with daily ZnONPs per os (Sigma–Aldrich, Cata-
log No. 721077, Seelze, Germany) at a dose of 10 mg/kg; (3)
diabetic + SNPs group (n = 10), which was administered with
SNPs per os (Sigma–Aldrich, Catalog No. 730793, Seelze,
Germany) at a daily dose of 10 mg/kg; (4) diabetic + insulin
group (n = 10), which was injected with subcutaneous dose of
insulin (0.6 units/50 g) for 30 constitutive days [13].
2.2. Ethical statement
All experimental procedures were performed in agreement
with the Saudi Arabian laws and University Guidelines for the
care and rights of experimental animals.
2.3. Sampling protocol
One gram of brain tissue was collected on liquid nitrogen and
then divided into different aliquots which were preserved
at −80 C until their use in biochemical and molecular biological
investigations.
2.4. Biochemical assay
Brain zinc and silver concentrations were analyzed by using
an inductively coupled plasma-atomic emission spectroscopy
with an ULTIMA 2 apparatus (Horiba Jobin Yvon, France).
Brain homogenate was used for determination of catalase
(CAT), glutathione peroxidase (GPx) and glutathione reductase
(GRD) activity by using a kit (Catalog No. NWK-CAT01, NWK-
GPX01 and NWK-GR01) purchased from Northwest Life Science
Specialties, Vancouver, Canada. SOD activity was determined byTable 1
Oligonucleotide primer sequences of SOD, CAT, GPx, GR and b-actin gene
Gene Oligonucleotide sequences
SOD F 50-ATGGGGACAATACACA
R 50-TCATCTTGTTTCTCGTG
CAT F 50-GTCCGATTCTCCACAGT
R 50-CGCTGAACAAGAAAGT
GPx F 50-CACAGTCCACCGTGTAT
R 50-AAGTTGGGCTCGAACC
GRD F 50-CCATGTGGTTACTGCAC
R 50-GTTCCTTTCCTTCTCCTG
b-actin F 50-TCACTATCGGCAATGTG
R 50-GCTCAGGAGGAGCAATusing Cayman SOD diagnostic kit (Catalog No. 706002, Cayman,
USA). Malondialdehyde (MDA) was analyzed by measuring the
production of thiobarbituric acid reactive substances by using
TBARS assay kit (Catalog No. 10009055, Cayman, USA). Total
antioxidant capacity (TAC) was determined by using a kit supplied
by Bio-diagnostic (Catalog No. TA 25 12, Giza, Egypt).
2.5. Molecular analysis
Brain SOD, CAT, GPx, GRD gene expressions were quanti-
ﬁed by using real-time PCR. Total RNA was isolated from tissue
samples by using the Qiagen RNeasy Mini kit (Catalog No.
74104). About 0.5 mg of total RNA, was used for production of
cDNAbyusingQIAGENLongRange 2StepRT-PCRkit (Catalog
No. 205920). About 5 mL of total cDNA was mixed with 12.5 mL
of 2× SYBR® Green PCR mix with ROX from Bio-Rad and
10 pmol/mL of each forward and reverse primer for the measured
genes. The house-keeping gene b-actin was used as a constitutive
control for normalization. Primers were designed by using Primer
3 software (http://bioinfo.ut.ee/primer3/) as per the published
gene sequences of SOD, CAT, GPx, GRD and b-actin in rats
(Table 1) fromNCBI database where all primers were provided by
Sigma Aldrich (Sigma–Aldrich Chemie GmbH, Steinheim, Ger-
many). PCR reactions were carried out in an Abi Prism 7300
(Applied Biosystems, USA). The RNA concentration in each
sample was determined from the cycle threshold values. The
mRNA expression levels were calculated relative to b-actin gene
mRNA levels by using the 2-DD CT method.
2.6. Statistical analysis
The obtained data were analyzed by using SPSS version 20
(IBM 1 New Orchard Road Armonk, New York 10504-1722,
United States). Data were presented as mean ± SD (n = 10).
Student's t-test was used to calculate the differences between
groups at P < 0.05.
3. Results
3.1. Effect of ZnONPs and SNPs on zinc levels in brain
tissue
Zinc levels in the brain tissue decreased signiﬁcantly in
diabetic group, compared with control group. Both SNPs and
insulin treatment protected the brain tissue against the bad effect
of diabetes. The ZnONPs carried the ability to increase zinc
levels in brain tissue in ZnONPs treated rats, compared with the
control group (Table 2).s.
Size (bp) Gene ID
AGGC-30 225 Z21917.1
GAC-30
CGC-30 272 AH004967.1
AACCTG-30
GCC-30 292 S50336.1
CACC-30
TTCC-30 171 NM_053906
AGC-30
CGG-30 260 NM_007393
GATG-30
Table 2
Biochemical investigations in all groups.
Parameters Control Diabetic Diabetic + ZnONPs Diabetic + SNPs Diabetic + insulin
Zinc (mg/g) 22.0 ± 4.0 14.0 ± 2.0** 32.0 ± 3.0*## 21.0 ± 5.0# 22.5 ± 3.0#
Silver (mg/g) 8.0 ± 1.0 7.0 ± 1.3 7.3 ± 1.5 13.0 ± 3.0*## 7.5 ± 2.0
SOD (mmol/mg wt.w/min) 32.0 ± 2.0 8.2 ± 2.0*** 25.0 ± 3.0*### 18.7 ± 1.5*# 10.3 ± 1.0**
CAT (mmol/H2O2 decomposed/mg P/min) 900.0 ± 20.0 500.0 ± 15.0
*** 790.0 ± 10.0*## 710.0 ± 20.0*# 550.0 ± 2.03**
GPx (mmol/mg P/min) 130.0 ± 13.0 48.3 ± 7.6*** 100.0 ± 10.0*### 90.0 ± 3.0*## 50.0 ± 4.0***
GRD (U/mg P) 6.5 ± 0.5 2.8 ± 0.3*** 6.3 ± 0.3### 4.4 ± 0.4*## 3.0 ± 0.5***
wt.w: Wet weight tissue. *: P < 0.05, **: P < 0.01, ***: P < 0.001, comparing to control group; #: P < 0.05, ##: P < 0.01, ###: P < 0.001, comparing to
diabetic group.
Table 3
Proﬁle of mRNA expression (relative expression to b-actin) of antioxidant genes in all groups.
Genes Control Diabetic Diabetic + ZnONPs Diabetic + SNPs Diabetic + insulin
SOD 1.100 ± 0.001 0.200 ± 0.003** 0.90 ± 0.01*## 0.700 ± 0.002*# 0.70 ± 0.09*#
CAT 1.300 ± 0.002 0.300 ± 0.001*** 1.00 ± 0.02*## 0.800 ± 0.010*# 0.60 ± 0.01*#
GPx 0.960 ± 0.060 0.440 ± 0.030** 0.90 ± 0.04## 0.720 ± 0.020*## 0.60 ± 0.05*#
GRD 0.900 ± 0.050 0.500 ± 0.002** 1.70 ± 0.30*### 1.000 ± 0.040## 0.70 ± 0.03*#
*: P < 0.05,**: P < 0.01,***: P < 0.001, comparing to control group; #: P < 0.05, ##: P < 0.01, ###: P < 0.001, comparing to diabetic group.
Table 4
Biochemical effect of ZnONPs, SNPs on MDA and TAC in brain tissue of diabetic rats.
Parameters Control Diabetic Diabetic + ZnONPs Diabetic + SNPs Diabetic + insulin
TAC (mmol/L/g wt. w) 6.10 ± 0.66 2.8 ± 0.3*** 6.6 ± 0.6### 5.7 ± 0.6## 4.00 ± 0.90*#
MDA (nmol/g wt.w) 0.95 ± 0.10 4.3 ± 0.3*** 1.6 ± 0.3### 1.1 ± 0.4## 2.50 ± 0.05*#
wt.w: Wet weight tissue. *: P < 0.05, **: P < 0.01, ***: P < 0.001, comparing to control group; #: P < 0.05, ##: P < 0.01, ###: P < 0.001, comparing to
diabetic group.
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tissue
The silver levels in the brain tissue were not changed in all
treated groups, except that SNPs treated rats showed a signiﬁ-
cant increase, compared with the other groups (Table 2).
3.3. Effect of ZnONPs and SNPs on antioxidant enzyme
activities in brain tissue
Both diabetic and diabetic + insulin treated rats showed a
signiﬁcant decrease in the activities of SOD, CAT, GPx and
GRD, compared with the control group. Either ZnONPs or SNPs
treatment had the ability to protect the antioxidant enzymes in
brain tissue against the bad effect of diabetes (Tables 2 and 3).
3.4. Effect of ZnONPs and SNPs on mRNA expression
levels of antioxidant genes in brain tissue
A signiﬁcant increase in mRNA expression levels of SOD,
CAT, GPx and GRD was shown in rats treated with ZnONPs
and SNPs, compared with the diabetic group (Tables 2 and 3).
3.5. Effect of ZnONPs and SNPs on MDA and TAC
levels in brain tissue
MDA levels were signiﬁcantly decreased while there was a
signiﬁcant increase in the TAC in the brain of ZnONPs and
SNPs treated rats when compared with diabetic or
diabetic + insulin group and control group (Table 4).4. Discussion
In the present study, we tended to examine the ameliorative
effect of both ZnONPs and SNPs on the oxidative stress
generated in brain cells of the diabetic rats. In the present study,
zinc and silver particles were increased signiﬁcantly in the brain
tissues of diabetic rats subjected to treatment with ZnONPs and
SNPs, with zinc levels of [(32 ± 3) and (21 ± 5) mg/g] and silver
levels of [(7.3 ± 1.5) and (13.0 ± 3.0) mg/g], compared with
control group containing zinc level of (22 ± 4) mg/g and silver
level of (8 ± 1) mg/g (Table 2). Long circulation of nanoparticles
leads to increase the chance of their passage to tissues, and hence
higher cellular uptake [14]. Once taken up in cells, particles
encounter an increasingly acidic environment as they move
from early to late endosomes and ﬁnally to lysosomes,
resulting in their dissolution [15]. Such phenomena may have
contributed to the observed increases of zinc and silver levels
in brain tissue in our study. ZnONPs and SNPs administration
to diabetic rats resulted in prevention of the decrease in the
activity and mRNA expression levels of SOD, CAT, GRD and
GPx. We tended the high activities and expression levels of
antioxidant enzymes in brains of ZnONPs and SNPs
administered rats to the effect of these nanoparticles to
improve the insulin secretion and amelioration of the oxidative
stress induced by impairment of glucose homeostasis [13].
These enzymes play a pivotal role in the elimination of free
radicals from the tissues so their high activities and expression
levels in brain cells protect them from the effect of oxidative
stress [16]. Diabetes mellitus is always associated with the
generation of ROS [2], and this is clear in our study proved by
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antioxidant enzymes in untreated diabetic rats. In the same
line of our study, the overproductions of superoxide free
radicals are eliminated by overexpression of antioxidant
enzymes [17]. Many authors have cited that diabetes mellitus is
usually associated with an increase in MDA production and
thus, increases the MDA levels in tissues and blood in
diabetic models [18]. Our results showed a signiﬁcant increase
in MDA levels in the brain of diabetic rats. We tended this
increase to the oxidative stress generated due to high glucose
levels as mentioned before. In ZnONPs and SNPs groups, the
levels of MDA were decreased in the brain tissues. The
reduction of MDA levels in the brain of rats administered with
nanoparticles may be due to the activity of these nanoparticles
to improve the insulin secretion and to increase the SOD,
CAT, GRD and GPx activities and mRNA expression [13]. To
demonstrate the TAC levels of the brain in diabetic rats and
diabetic rats administered with ZnONPs and SNPs, the TAC
was measured in the brains of all rats. The highest capacity
was observed in diabetic rats administered with ZnONPs
followed by diabetic rats administered with SNPs, compared
to diabetic group and control group (Table 4). We contended
that the high TAC in nanoparticles administered rats was due to
the ability of these particles to improve the antioxidant power of
the cells proved recently by Kunjiappan et al. [19]. In all
examined rats, the effect of ZnNPs and SNPs was more
obvious than the insulin in diabetic rats. There are more
improvements in total antioxidant power in the brain of
diabetic rats administered with nanoparticles than those treated
with insulin. Up till now, we have not a clear explanation
about the action of these nanoparticles. Yet, the speed by
which these nanoparticles were uptaken by the cells [14,15],
and its ability to induce endogenous insulin secretion [13], may
be the usual cause of their ability to improve the antioxidant
capacity in the brain cells. ZnONPs and SNPs are potent
agents for improvement of the antioxidant power of brain
cells. They have the ability to protect brain cells from the
oxidative stress generated in diabetes mellitus.
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